SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Fate Therapeutics’ FT819 Shows Renal Response in Two Lupus Nephritis Patients

Two patients showed a renal response at six months in the Phase 1 trial.

FATE

Related stories